肿瘤切除手术诱发术后复发的机制及纠正策略研究进展

手术切除是多数肿瘤治疗的基础策略，复发和转移是恶性肿瘤手术治疗失败的主要原因。临床上多种类型的肿瘤患者会在术后1 ~ 2年内出现复发风险，导致复发事件高发。尽管目前手术治疗手段已经取得极大进步，仍无法完全避免肿瘤患者术后复发。本文主要从激活交感神经系统、凝血系统、激发炎症、诱导免疫抑制等方面介绍手术切除诱发肿瘤复发转移机制的复杂性，并围绕这些机制介绍相关纠正策略，为提升肿瘤手术治疗效率提供重要参考，也为术后复发纠正策略的设计提供启发。

Surgery is a mainstay treatment for patients with solid tumors. However， recurrence and metastasis remain the major reasons why surgical treatment for malignant tumors can fail. Clinically， patients with various tumor types are most susceptible to recurrence within one to two years post-surgery， resulting in a significantly high incidence of recurrence events. Despite significant progress in surgical treatment， tumor recurrence following surgery cannot be entirely prevented. This paper delves into the complexity of the mechanism wherein surgical resection promotes tumor recurrence and metastasis by examining the activation of the sympathetic nervous system and coagulation system， the stimulation of inflammation， and the induction of immune suppression. The paper also introduces relevant corrective strategies based on these mechanisms. These findings not only serve as an essential reference for enhancing the efficacy of tumor surgical treatment， but also provide insights for designing postoperative relapse correction strategies.

PDF(771 KB)

betway必威登陆网址 (betway.com )学报 ›› 2023, Vol. 44 ›› Issue (7) : 535-540. DOI: 10.3969/j.issn.2097-0005.2023.07.012

综述

肿瘤切除手术诱发术后复发的机制及纠正策略研究进展

作者信息 +

Research progress on mechanism and correction strategy of tumor recurrence promoted by resection

Author information +

文章历史 +

收稿日期	出版日期
2023-04-11	2023-07-25
发布日期
2023-09-12

摘要

Abstract

导出引用

李彬, 冯锋, 刘富垒.肿瘤切除手术诱发术后复发的机制及纠正策略研究进展[J]. betway必威登陆网址 (betway.com )学报. 2023, 44(7): 535-540 https://doi.org/10.3969/j.issn.2097-0005.2023.07.012

Bin LI, Feng FENG, Fulei LIU.Research progress on mechanism and correction strategy of tumor recurrence promoted by resection[J]. Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences. 2023, 44(7): 535-540 https://doi.org/10.3969/j.issn.2097-0005.2023.07.012

参考文献

1	Matzner P， Sandbank E， Neeman E， et al. Harnessing cancer immunotherapy during the unexploited immediate perioperative period［J］. Nat Rev Clin Oncol， 2020， 17（5）： 313.
2	Colleoni M， Sun Z， Price KN， et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up： results from the international breast cancer study group trials I to V［J］. J Clin Oncol， 2016， 34（9）： 927.
3	Tsilimigras DI， Bagante F， Moris D， et al. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria［J］. Ann Surg Oncol， 2020， 27（7）： 2321.
4	Tohme S， Yazdani HO， Al-Khafaji AB， et al. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress［J］. Cancer Res， 2016， 76（6）： 1367.
5	Chen Z， Zhang P， Xu Y， et al. Surgical stress and cancer progression： the twisted tango［J］. Mol Cancer， 2019， 18（1）： 132.
6	Cheng X， Zhang H， Hamad A， et al. Surgery-mediated tumor-promoting effects on the immune microenvironment［J］. Semin Cancer Biol， 2022， 86（Pt 3）： 408.
7	Mahvi DA， Liu R， Grinstaff MW， et al. Local cancer recurrence： the realities， challenges， and opportunities for new therapies［J］. CA Cancer J Clin， 2018， 68（6）： 488.
8	Mohme M， Riethdorf S， Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape［J］. Nat Rev Clin Oncol， 2017， 14（3）： 155.
9	Albrengues J， Shields MA， Ng D， et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice［J］. Science， 2018， 361（6409）： eaao4227.
10	Dillek?s H， Rogers MS， Straume O. Are 90% of deaths from cancer caused by metastases？［J］. Cancer Med， 2019， 8（12）： 5574.
11	Xu M， Hu K， Liu Y， et al. Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy［J］. Nat Commun， 2021， 12（1）： 3187.
12	Walens A， Lin J， Damrauer JS， et al. Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence［J］. Nat Commun， 2020， 11（1）： 5017.
13	Hiller JG， Perry NJ， Poulogiannis G， et al. Perioperative events influence cancer recurrence risk after surgery［J］. Nat Rev Clin Oncol， 2018， 15（4）： 205.
14	Neeman E， Ben-Eliyahu S. Surgery and stress promote cancer metastasis： new outlooks on perioperative mediating mechanisms and immune involvement［J］. Brain Behav Immun， 2013， 30 Suppl（Suppl）： S32.
15	Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence［J］. J Transl Med， 2018， 16（1）： 8.
16	Sloan EK， Priceman SJ， Cox BF， et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer［J］. Cancer Res， 2010， 70（18）： 7042.
17	Le CP， Nowell CJ， Kim-Fuchs C， et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination［J］. Nat Commun， 2016， 7： 10634.
18	Rosenne E， Sorski L， Shaashua L， et al.In vivosuppression of NK cell cytotoxicity by stress and surgery： glucocorticoids have a minor role compared to catecholamines and prostaglandins［J］. Brain Behav Immun， 2014， 37： 207.
19	Haldar R， Ricon-Becker I， Radin A， et al. Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis， immunity， and inflammation in colorectal cancer： a randomized controlled trial［J］. Cancer， 2020， 126（17）： 3991.
20	Hashemi Goradel N， Najafi M， Salehi E， et al. Cyclooxygenase-2 in cancer： a review［J］. J Cell Physiol， 2019， 234（5）： 5683.
21	Thaker PH， Han LY， Kamat AA， et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma［J］. Nat Med， 2006， 12（8）： 939.
22	Hondermarck H， Jobling P. The sympathetic nervous system drives tumor angiogenesis［J］. Trends Cancer， 2018， 4（2）： 93.
23	McCrath DJ， Cerboni E， Frumento RJ， et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction［J］. Anesth Analg， 2005， 100（6）： 1576.
24	Chiang SPH， Cabrera RM， Segall JE. Tumor cell intravasation［J］. Am J Physiol Cell Physiol， 2016， 311（1）： C1.
25	Seth R， Tai LH， Falls T， et al. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model［J］. Ann Surg， 2013， 258（1）： 158.
26	Palumbo JS， Talmage KE， Massari JV， et al. Platelets and fibrin（ogen） increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells［J］. Blood， 2005， 105（1）： 178.
27	Ren J， He J， Zhang H， et al. Platelet TLR4-ERK5 axis facilitates NET-Mediated capturing of circulating tumor cells and distant metastasis after surgical stress［J］. Cancer Res， 2021， 81（9）： 2373.
28	Sylman JL， Mitrugno A， Tormoen GW， et al. Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer［J］. Converg Sci Phys Oncol， 2017， 3（2）： 023001.
29	Peiseler M， Kubes P. More friend than foe： the emerging role of neutrophils in tissue repair［J］. J Clin Invest， 2019， 129（7）： 2629.
30	Chen Q， Zhang L， Li X， et al. Neutrophil extracellular traps in tumor metastasis： pathological functions and clinical applications［J］. Cancers （Basel）， 2021， 13（11）： 2832.
31	Kalogeris T， Baines CP， Krenz M， et al. Ischemia/reperfusion［J］. Compr Physiol， 2016， 7（1）： 113.
32	Selders GS， Fetz AE， Radic MZ， et al. An overview of the role of neutrophils in innate immunity， inflammation and host-biomaterial integration［J］. Regen Biomater， 2017， 4（1）： 55.
33	Zappalà G， McDonald PG， Cole SW. Tumor dormancy and the neuroendocrine system： an undisclosed connection？［J］. Cancer Metastasis Rev， 2013， 32（1/2）： 189.
34	Erpenbeck L， Sch?n MP. Neutrophil extracellular traps： protagonists of cancer progression？［J］. Oncogene， 2017， 36（18）： 2483.
35	Derynck R， Turley SJ， Akhurst RJ. TGFβ biology in cancer progression and immunotherapy［J］. Nat Rev Clin Oncol， 2021， 18（1）： 9.
36	Kessenbrock K， Plaks V， Werb Z. Matrix metalloproteinases： regulators of the tumor microenvironment［J］. Cell， 2010， 141（1）： 52.
37	Batlle E， Massagué J. Transforming growth factor-β signaling in immunity and cancer［J］. Immunity， 2019， 50（4）： 924.
38	Van Der Bij GJ， Oosterling SJ， Beelen RH， et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer［J］. Ann Surg， 2009， 249（5）： 727.
39	Neeman E， Zmora O， Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence： perioperative targeting of catecholamines and prostaglandins［J］. Clin Cancer Res， 2012， 18（18）： 4895.
40	Sorski L， Melamed R， Matzner P， et al. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition［J］. Brain Behav Immun， 2016， 58： 91.
41	Krall JA， Reinhardt F， Mercury OA， et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy［J］. Sci Transl Med， 2018， 10（436）： eaan3464.
42	Tai LH， de Souza CT， Bélanger S， et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells［J］. Cancer Res， 2013， 73（1）： 97.
43	Tang F， Tie Y， Tu C， et al. Surgical trauma-induced immunosuppression in cancer： recent advances and the potential therapies［J］. Clin Transl Med， 2020， 10（1）： 199.
44	Predina J， Eruslanov E， Judy B， et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery［J］. Proc Natl Acad Sci U S A， 2013， 110（5）： E415.
45	Phillips JD， Knab LM， Blatner NR， et al. Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer［J］. Cancer Immunol Immunother， 2015， 64（9）： 1185.
46	Saito Y， Shimada M， Utsunomiya T， et al. Regulatory T cells in the blood： a new marker of surgical stress［J］. Surg Today， 2013， 43（6）： 608.
47	Wang B， Zhang Z， Liu W， et al. Targeting regulatory T cells in gastric cancer： pathogenesis， immunotherapy， and prognosis［J］. Biomed Pharmacother， 2023， 158： 114180.
48	Wang Y， Ding Y， Guo N， et al. MDSCs： key criminals of tumor pre-metastatic niche formation［J］. Front Immunol， 2019， 10： 172.
49	Veglia F， Sanseviero E， Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity［J］. Nat Rev Immunol， 2021， 21（8）： 485.
50	Gabrilovich DI， Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system［J］. Nat Rev Immunol， 2009， 9（3）： 162.
51	Lu Z， Zou J， Li S， et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches［J］. Nature， 2020， 579（7798）： 284.
52	Wang J， Yang L， Yu L， et al. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer［J］. Oncotarget， 2017， 8（10）： 17050.
53	Brecht K， Weigert A， Hu J， et al. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2［J］. FASEB J， 2011， 25（7）： 2408.
54	Lamkin DM， Srivastava S， Bradshaw KP， et al. C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages［J］. Brain Behav Immun， 2019， 80： 839.
55	Pan Y， Yu Y， Wang X， et al. Tumor-associated macrophages in tumor immunity［J］. Front Immunol， 2020， 11： 583084.
56	Coffey JC， Smith MJ， Wang JH， et al. Cancer surgery： risks and opportunities［J］. Bioessays， 2006， 28（4）： 433.
57	Van Der Hage JA， Van De Velde CJ， Julien JP， et al. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer （EORTC） Trial 10854［J］. Eur J Cancer， 2001， 37（17）： 2184.
58	Hua Y， Bergers G. Tumors vs. chronic wounds： an immune cell's perspective［J］. Front Immunol， 2019， 10： 2178.
59	Wijeysundera DN， Duncan D， Nkonde-Price C， et al. Perioperative beta blockade in noncardiac surgery： a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery： a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines［J］. J Am Coll Cardiol， 2014， 64（22）： 2406.
60	Santangelo G， Faggiano A， Toriello F， et al. Risk of cardiovascular complications during non-cardiac surgery and preoperative cardiac evaluation［J］. Trends Cardiovasc Med， 2022， 32（5）： 271.
61	Cameron D， Piccart-Gebhart MJ， Gelber RD， et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer： final analysis of the HERceptin Adjuvant （Hera） trial［J］. Lancet， 2017， 389（10075）： 1195.
62	Miller KD， O'Neill A， Gradishar W， et al. Double-blind phase Ⅲ trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer （E5103）［J］. J Clin Oncol， 2018， 36（25）： 2621.